Marshall Wace, LLP Cytek Biosciences, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 134,286 shares of CTKB stock, worth $738,573. This represents 0.0% of its overall portfolio holdings.
Number of Shares
134,286
Previous 261,352
48.62%
Holding current value
$738,573
Previous $888,000
47.64%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CTKB
# of Institutions
150Shares Held
72.8MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$93.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.93MShares$38.1 Million0.0% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$36.6 Million0.69% of portfolio
-
Brown Capital Management LLC Baltimore, MD4.96MShares$27.3 Million0.74% of portfolio
-
State Street Corp Boston, MA4.08MShares$22.5 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $740M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...